LAUNCHES, PROMOTIONS, MERCHANDISING, EVENTS AND OTHER THINGS TO KEEP YOU IN THE KNOW.
MACULOGIX ACADEMY TEACHES ADAPTDX USERS
MacuLogix, Inc. has launched its AMD Academy, an online learning community available at no cost for current users of the AdaptDx dark adaptometer. The launch features 21 video-based learning modules to educate new users about how to prepare and run the test, how to manage patient data and more. Experienced AdaptDx users can also access the learning modules at any time to revisit certain topics and to gain or share helpful tips on the discussion forum. The company plans to add learning modules, including best practices and practice workflow. General education on age-related macular degeneration will be added in the future. Go to MacuLogix.com.
ALCON EXPERIENCE ACADEMY INCLUDES TRAINING
Alcon, a division of Novartis, has unveiled the Alcon Experience Academy, which offers face-to-face training and online educational resources for healthcare professionals, including eyecare practitioners. As part of this effort, Alcon is launching a new online portal with a library of educational materials, including more than 500 training videos, with additional content added regularly to the home screen. It will also feature webcasts developed by eyecare specialists from around the world, along with personalized videos and curricula across several disease states and focus areas. The website materials primarily focus on real-world surgical case studies, and resources specific to optometry are due to be released early next year. Go to AlconExperienceAcademy.com.
BLANCHARD TEACHES STUDENTS ABOUT SCLERAL LENSES
Blanchard Contact Lenses has launched the Onefit Scleral Lens Excellence Award program in partnership with optometric educational institutions across the country. The program will provide third- and fourth-year students with opportunities to develop and enhance their experience with scleral lenses. Students who complete each element of the four-part program will receive the Onefit Scleral Lens Excellence Award along with a certificate redeemable for their choice of a Onefit or Onefit MED diagnostic fitting set. Information is available through the schools themselves, or interested students can call Blanchard at 800.367.4009 and ask for Beth Clark, director of marketing communications. Go to BlanchardLab.com/products/Onefit or BlanchardLab.com/products/Onefit-Med.
J&J LAUNCHES NEW LASIK TREATMENT
Johnson & Johnson Vision has launched the iDESIGN Refractive Studio, which allows doctors to take a precise measurement of the eye inside and out so that each patient can receive a personalized LASIK procedure. The device is approved for myopia, hyperopia, and mixed astigmatism and is indicated for wavefront-guided monovision LASIK in presbyopic myopic patients. The iDESIGN Refractive Studio takes five measurements—wavefront aberrometry, wavefront refraction, corneal topography, keratometry and pupillometry—in a single one-click capture sequence. Go to JJVIsion.com.
B+L GEL RESOLVES POST-CATARACT SURGERY PAIN
The Sept. 4, 2018 Journal of Cataract and Refractive Surgery includes results of Bausch + Lomb’s Phase 3 multicenter study that evaluated the clinical safety and efficacy of submicron loteprednol etabonate ophthalmic gel, 0.38%. Results of the double-masked, vehicle-controlled study showed that this investigational formulation was significantly more effective than the vehicle in completely resolving ocular inflammation and pain following cataract surgery and that it had an acceptable safety profile regardless of whether it was administered two or three times per day. Submicron loteprednol etabonate ophthalmic gel, 0.38% has a reduced concentration and reduced dosing frequency versus existing formulations of loteprednol etabonate. Go to Bausch.com.
MATI’S EVOLUTE ALLEVIATES POST-CATARACT PAIN
Also in post-op cataract care, Mati Therapeutics Inc. has completed a planned interim analysis of an ongoing Phase II clinical trial evaluating the safety and efficacy of nepafenac delivered in the Evolute sustained ocular drug delivery platform in 75 patients who underwent cataract surgery. The primary endpoint is to evaluate pain, and the secondary endpoint is to evaluate inflammation following surgery. Pain scores favored nepafenac over placebo at days one, two and three post-op. At day three, 71% of patients treated with nepafenac experienced no pain versus 12% in the placebo arm. Post-operative inflammation, as determined by cell and flare scores, also favored the Evolute arm. The treatment was generally well tolerated, with no unexpected side effects reported. Go to MatiTherapeutics.com.
Think About Your Eyes, a national public awareness campaign about the importance of scheduling an annual eye exam with an optometrist, has added the California, Delaware, and Massachusetts state optometric associations to the current group of leadership states, bringing the total number of state associations supporting the campaign to 44 and the number of listings to 22,000.
A partnership between the California Optometric Association, Anthem Blue Cross Medi-Cal Health Plan, and Ampla Health helped Chico residents build relationships with the local community health center and healthcare providers and learn about how to prevent and manage diabetes to avoid such consequences as blindness and amputations.
Andrew J. Viterbi, co-founder and retired vice chairman and chief technical officer of Qualcomm Inc., has donated $50 million to the University of California, San Diego, which will go toward The Viterbi Family Department of Ophthalmology, The Viterbi Family Vision Research Center and six new endowed chairs for faculty.
EyePoint Pharmaceuticals has elected Göran Ando, MD, as its next chairman, succeeding David J. Mazzo, PhD, who will remain on the board and serve as chair of the compensation committee.
Clearside Biomedical, Inc. has appointed Lester Rodríguez as vice president, quality.
Eyevance Pharmaceuticals has acquired Paragon BioTeck, which recently reformulated its FRESHKOTE family of lubricant eye drops as a preservative-free product available in a multi-dose bottle and in single-unit vials.
Kodiak Sciences Inc. has completed enrollment of patients in the company’s phase 1 safety and tolerability study of KSI-301, an intravitreally administered anti-VEGF agent, for the treatment of neovascular age-related macular degeneration and diabetic eye disease.
Thomas J. Chirillo has been named chief commercial officer with neurolens.
The U.S. Food and Drug Administration has acted on two supplemental Biologics License Applications from Regeneration Pharmaceuticals, Inc. The FDA approved the application for using EYLEA (aflibercept injection) in patients who have wet AMD and accepted for review the application for using EYELEA to treat diabetic retinopathy.
In other news, the FDA:
• Approved Dompé’s Oxervate (cenegermin) for the treatment of neurotrophic keratitis.
• Approved INVELTYS (loteprednol etabonate 0.1%), a twice-daily ocular corticosteroid from Kala Pharmaceuticals, Inc. for treating postoperative inflammation and pain following ocular surgery.
• Granted Fast-Track designation to MeiraGTx Holdings Plc for its AAV-CNGB3 gene therapy product candidate for the treatment of achromatopsia.